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Introduction
Human polymorphonuclear neutrophils (PMNs) have
been postulated to have both beneficial and detrimental
roles in the immune response to various tumors [1,2].
The classical antitumor effect of the neutrophils includes
the antibody-dependent cell cytotoxic, the directed cell
killing by reactive oxygen species, as well as calprotectin
[2]. Furthermore, PMNs can play a role in cytokine-
induced tumor rejection, in cooperation with CD8+T
lymphocytes [2]. It was well established that human
PMNs synthesize and secrete cytokines that influence
the different effector cells recruitment and modulation
within the tumor microenvironment [1,3]. 
Neutrophils are known to produce ligands of the
TNF family, such as TNF-α, Fas ligand, CD30 ligand,
B-lymphocyte stimulator (BLyS) and tumor necrosis
factor (TNF)-related apoptosis-inducing ligand
(TRAIL) [1,4-6]. In contrast to other members of the
TNF superfamily, whose expression is tightly regulat-
ed and which are often only transiently expressed on
activated cells, TRAIL is expressed constitutively in a
wide range of cells, involving neutrophils [6,7].
TRAIL (Apo-2L) is a type II transmembrane pro-
tein that was originally identified and cloned on the
basis of sequence homology to the Fas ligand and TNF
[7-9]. Endogenous TRAIL can be biologically effec-
tive not only as an integral membrane protein but also
as a soluble cytokine which is released by human neu-
trophils [4,6,7]. 
TRAIL and sTRAIL can selectively induce apopto-
sis in a number of cell types, including many trans-
formed and tumor cells [7-10]. It is interesting to note
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that most normal cells are not sensitive to TRAIL-
mediated apoptosis [8,9]. 
TRAIL exerts its biological activity by interacting
with a complex system of two death receptors TRAIL-
R1(DR4) and TRAIL-R2(DR5), and three "decoy
receptors" TRAIL-R3(DcR1), TRAIL-R4(DcR2), as
well as osteoprotegerin (OPG). TRAIL-R1 and
TRAIL-R2 containing cytoplasmic "death domains"
signal apoptosis [7-10]. TRAIL-R4 has a truncated,
non-functional cytoplasmic death domain, while
TRAIL-R3 lacks a cytosolic region and is anchored to
the plasma membrane. Both receptors are therefore
incapable of transmitting an apoptosis signal [9]. OPG
is a soluble receptor for TRAIL, and may also act as a
soluble decoy receptor [11].  
The TRAIL receptors expression were found in
human neutrophils. Kamohara et al. reported that neu-
trophils express death receptor DR5 and "decoy recep-
tor" DcR1 [4]. The extracellular domains of DR5 and
DcR1 are expressed in a soluble, monomeric form
[12,13]. Soluble DR5 receptor (sDR5) is able to bind
TRAIL and to modulate TRAIL-mediated reactions
[14]. For example, Myashita et al. demonstrated that
soluble DR5 receptor significantly inhibits TRAIL-
induced apoptosis [13].    
The preferential activity of TRAIL against cancer
cells has generated hopes for its potential use in cancer
therapy as a single remedy or in combination with
chemotherapy and radiotherapy [8,15]. For example, it
was observed that the combination of cisplatin and
TRAIL resulted in synergistic induction of cell death
in head and neck squamous cell carcinoma - 6
(HNSCC-6) and HNSCC-30 cells [15]. Recent data of
Teng et al. demonstrated that HNSCC tumor cells
express TRAIL-R1 and TRAIL-R2 that make them
sensitive to TRAIL-mediated apoptosis induced by
different cells [16]. 
On the basis of the above findings, we examined
the release of the soluble form of TRAIL by neu-
trophils derived from patients with oral cavity cancer.
Simultaneously, we estimated the ability of PMNs of
this patients to the release soluble form of DR5 recep-
tor, a natural regulatory protein of TRAIL. Examina-
tions above can be helpful in the evaluation a potential
role of neutrophils in TRAIL-mediated reactions in
patients with oral cavity cancer. 
Materials and methods
Sample material. 20 patients, aged from 45 to 49 years,  with
squamous cell carcinoma of oral cavity treated in the Department
of Oral and Maxillofacial Surgery, Medical University of Bialystok
were examined. Examinations were carried out on patients before
the treatment and 3 weeks after the surgical removal of the tumor
mass. Patients did not receive any treatment or medication before
examination. Study results were analyzed taking into account a
clinical course of disease according to TNM staging classification
[17]. There were no clinical signs of infection observed in patients.
In all patients no significant leukocytosis was observed. The mean
number of white cells in the blood of all patients before treatment
was 6.183/μL (from 3.8 to 8.953/μL), after treatment was 5.63/mL
(from 4.0 to 8.253/mL). Control subjects (n=15) were healthy peo-
ple aged from 30 to 53 years (mean 41.5 year). 
Preparation of human neutrophils (PMN) and peripheral
blood mononuclear cells (PBMC). For comparative purposes we
performed examinations in autologous peripheral blood mononu-
clear cells (PBMC). 
PMNs and PBMC were isolated from whole blood treated with
EDTA by density centrifugation using Polymorphoprep (Axis-
Shield, Oslo, Norway) (density - 1.113 g/mL). Five mL of whole
blood were layered on 5 mL of Polymorphoprep in a 12-mL tube
and centrifuged at 500 × g for 30 min at room temperature. The
neutrophils in the lower band and mononuclear cells in the higher
band were harvested using a Pasteur pipette and washed with PBS.
Neutrophils were suspended in RPMI 1640 medium (Invitrogen,
Carlsbad, CA) and mononuclear cells in Hanks solution to provide
5 × 106 cells/mL. The purity of isolated PMNs and PBMC was
determined by May-Grunewald-Giemsa-staining. The viability of
PMNs and PBMC measured using FITC-conjugated annexinV and
propidium iodide (PI) (Apotest-FITC, DakoCytomation, Den-
mark) after isolation was >98%. The fluorescence intensity of cells
was measured using EPICS XL (Beckman Coulter Epics XL-
MCL).
Culture of PMN and PBMC. The cells in the culture medium
containing 10% autologous serum, 10 U/mL penicillin and 50
ng/mL streptomycin were incubated in flat-bottomed 96-well
plates (Microtest III-Falcon, Franklin Lakes, USA) for 20 h at
37°C in a humidified incubator with 5% CO2 (NUAIRETN).  The
viability of PMNs measured after 20 h incubation was >94%,
PBMC was >95%.
Western blot analysis. After incubation, cells were washed twice
with cold phosphate buffered saline (PBS) to remove excess pro-
teins. Cells were lysed directly in the presence of inhibitor protease
(Sigma-Aldrich, CHEMIE GmbH P.O. Steinheim, Germany) by
sonication using Vibra-Cell Ultrasonic Processor (Sonics&Materi-
als, Inc., USA). After that the remaining cell debris was removed
by centrifugation at 10000×g for 15 min at room temperature and
supernatants were collected and stored in -70°C. 
The amount of protein was determined using the Lowry
method and the absorbance was measured in a Beckman DU® 640
at 750 nm. Each lane was loaded with 100 µg of protein, and
Western blot was performed as described.
Cytoplasmic protein fractions of PMN  and PBMC  were ana-
lyzed for the presence of  TRAIL and DR5 proteins by western
blotting. Protein fractions were suspended in Laemmli buffer (Bio-
Rad Laboratories, Herkules CA, USA) and than were elec-
trophorezed  on SDS-PAGE. The resolved protein was transferred
onto 0.2 μm pore-sized nitrocellulose (Bio-Rad Laboratories,
Herkules CA, USA). The nitrocellulose was incubated  at +4°C  for
18 h with the primary polyclonal antibodies anti-TRAIL or anti-
DR5, respectively (Alexis, Carlsbad CA, USA). After washing
with 0,1% TBS-T, the membrane was incubated at room tempera-
ture for 1 h with alkaline phosphatase anti-mouse IgG Abs (Vector
Laboratories, Burlingame, CA, USA). Immunoreactive protein
bands were visualized following the addition of BCIP/NBT Liquid
Substrate System (Sigma-Aldrich, CHEMIE GmbH P.O. Stein-
heim, Germany). 
The measurement of soluble TRAIL and DR5 concentrations.
Soluble TRAIL and DR5 levels in the culture supernatants of PMN
and PBMC were confronted with their serum levels. Soluble
TRAIL concentration was assessed using ELISA kit (R&D Sys-
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tems, Minneapolis, USA). A monoclonal antibody specific for
human TRAIL has been pre-coated onto a microplate. One hundred
μL of Assay Diluent RD1S and 50 μL standand, control and sam-
ple were added to the wells and incubated for 2 h at room tempe-
rature on a horizontal orbital microplate shaker set at 500 rpm.
After washing, 200 μL Conjugate was added to the wells, incubat-
ed 2 h on the shaker, washed four times. Next, a substrat solution
for peroxidase was added to induce a colored reaction and incu-
bated 30 min. The color development was stopped and the intensi-
ty of the color was determined by reading absorbance at 540 nm on
a microplate reader UVM340 (ASYS, HITECH, G.m.b.H).
Soluble DR5 concentration was assessed using ELISA kit
(BioSource Int., USA). A monoclonal antibody specific for human
DR5 has been pre-coated onto a wells of the microplate. One hun-
dred μL of Standard Diluent Buffer to zero wells and 100 μL of
standards and samples were added to the appropriate wells and
incubated for 2 h at room temperature. After washing four times,
100 μL of Conjugate was added to the wells, incubated 1 h, washed
four times. Next, 100 μL of Streptavidin-HRP Working Solution
was added to the wells and incubated 30 min.. After washing, 100
μL of Stabilized Chromogen was added to the wells and incubated
30 min. The color development was stopped and the intensity of
the color  was determined by reading absorbance at 450 nm on the
microplate reader UVM340 (ASYS, HITECH, G.m.b.H).  
Ethical issues. The study was approved by the Ethics Committee
of the Medical University of Bialystok and all patients submitted
their consent in writing.
Statistical methods. Statistical analysis was performed with a sta-
tistics package Statistica 6.0 software (Statsoft, Cracow, Poland).
Non-parametric U Mann-Whitney test was used. Results were
expressed as mean   SD. The p values smaller than 0.05 were con-
sidered statistically significant. Bands intensity in blots were quan-
tified using LabImage 1 D gel software.
Results
The different expression of TRAIL and DR5 
in the lysates of PMN and PBMC
Western blot analysis showed that the lysates of PMN
and PBMC contained a 42 kDa protein that was
stained by an anti-TRAIL polyclonal antibody (Fig. 1).
PMN and PBMC of  whole cancer patient group
expressed decreased TRAIL protein in comparison
with the control group (Fig. 1). There were no signifi-
cant differences in TRAIL expression between PMN
and PBMC in patients as well as in the control group. 
The presence of cellular DR5, a 58 kDa protein, in
PMN and PBMC lysates was confirmed using specific
polyclonal antibody anti-DR5. There were no differ-
ences in expression of DR5 between cells of patients
and the control group (Fig. 1). DR5 expression in
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Fig. 1. Western blot analysis of TRAIL and DR5 in PMN and PBMC cells from control and patients with oral cavity cancer before treat-
ment. A: PMN of control; B: PBMC of control; C: PMN of cancer patients; D: PBMC of cancer patients. Representative of a few inde-
pendent experiments are shown. The diagrams are shown statistical analysis of Western blot of TRAIL and DR5 estimated by arbitrary
units.*statistical difference with control (p<0.05); **statistical difference between PMN and PBMC (p< 0.05).
PBMC of  patients was higher as compared to its
expression in PMN. 
A comparison of the intensities of the bands corre-
sponding to TRAIL in PMN and PBMC lysates derived
from patients before and after treatment revealed a
weaker expression  of TRAIL in PMN of patients after
treatment in comparison with its expression in examina-
tion before treatment (Fig. 2). Additionally, TRAIL
expression protein in PBMC of patients after treatment
was higher than in PMN. In contrast, DR5 expression in
PMN and PBMC lysates was on the same level in
patients before and after treatment.
sTRAIL and sDR5 concentrations 
in supernatants of cells and the serum
The ELISA data showed no differences in the concen-
trations of sTRAIL in the culture supernatants of
PMNs between all patients with oral cavity cancer and
the healthy control (Table 1). Analysis of results
according to TNM classification indicated that release
of sTRAIL by PMN from cancer patients in Stage IV
before surgery treatment was significantly lower in
comparison with its release by cells from patients in
Stage II and the control group. There were no differ-
ences in secretion of sTRAIL by PMN between
patients in Stage II before treatment and the control.
Examinations carried out in patients in Stage II after
treatment showed insignificantly decreased secretion
of sTRAIL by PMN and the same secretion of its by
PMN from patients in Stage IV as compared to the
studies before treatment (Table 1).
In contrast to PMN, PBMC from all patients before
treatment, irrespective of clinical stage, secreted lower
amounts of sTRAIL in comparison with the control
group (Table 2). There were no differences in secretion
of sTRAIL between patients in Stage II and in Stage
IV. After treatment the changes in the concentrations of
sTRAIL in the supernatants of PBMC from all patients
were not significant. 
In the present study the ability of PMN and PBMC
of oral cavity cancer patients to release sDR5 receptor
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Fig. 2. Western blot analysis of TRAIL and DR5 protein expression in PMN and PBMC of cancer patients in Stage II. A: PMN from
patients before treatment; B: PBMC from patients before treatment; C: PMN from patients after treatment; D: PBMC from patients after
treatment. The diagrams are shown statistical analysis of Western blot of TRAIL and DR5 estimated by arbitrary units. astatistical differ-
ence with TRAIL expression before treatment (p<0.05); **statistical difference between PMN and PBMC after treatment (p<0.05).
was also examined. However, we did not find any dif-
ferences between the concentrations of sDR5 in the
culture supernatants of patient cells and the control
cells (Table 1 and 2).  
The concentrations of sTRAIL and sDR5 in the
culture supernatants of PMN and PBMC were con-
fronted with their serum levels. Soluble TRAIL con-
centrations in the serum of all cancer patients before
treatment were not different from the concentrations
in the control group (Table 3). However, the concen-
tration of sTRAIL in the serum of patients in Stage
II was higher in comparison to the control group.
After treatment, the serum levels sTRAIL in all
patients were significantly lower as compared to the
values obtained in examination before treatment.
In contrast to sTRAIL, there were no differences in
the serum sDR5 concentrations between the patients
and the control group (Table 3).
There were no correlations between the serum lev-
els of sTRAIL and sDR5 and their concentrations in
the culture supernatants of PMN or PBMC.
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Table 1. The mean concentrations of sTRAIL and sDR5 in the culture supernatants of PMN from oral cavity cancer patients. *significant
difference with the control (p<0.05); asignificant difference between examinations before and after treatment (p<0.05); bsignificant dif-
ferences between patients in Stage II and IV (p<0.05).
Table 2. The mean concentrations of sTRAIL and sDR5 in the culture supernatants of PBMC from oral cavity cancer patients. *signifi-
cant difference with the control (p<0.05).
Table 3. Serum concentrations of sTRAIL and sDR5 in patients with oral cavity cancer and control group. *significant difference with
the control (p<0.05); asignificant difference between examinations before and after treatment (p<0.05).
Discussion
The role of human neutrophils in TRAIL-mediated
reactions was confirmed by Tecchio et al. who showed
that these cells releasing sTRAIL exhibit proapoptotic
activities towards TRAIL-sensitive chronic myeloid
leukemic cell lines [6]. Furthermore, Koga et al.
reported that when Jurkat cells, a well-known
leukemic cell line susceptible to TRAIL-mediated
killing, were cultured with neutrophils in the presence
of IFN-γ, the number of Jurkat cells undergoing apop-
tosis increased [18]. 
In the present study we demonstrated an interesting
relation between the ability of PMNs and autologous
PBMC to the secretion of sTRAIL in oral cavity can-
cer patients. Unchanged release sTRAIL by PMNs of
patients in Stage II was accompaying the decrease of
the ability of PBMC to the secrete of this protein.
Since during the growing phase tumors are infiltrated
first by neutrophils, then macrophages and T cells,
retained secretion of sTRAIL by PMNs in the
microenvironment of tumor can lead to the TRAIL-
mediated apoptosis of cancer cells at early phase of
disease [19]. Its observation appears as especially
important, particularly in the light of the fact that pri-
mary oral squamous carcinoma cells are more suscep-
tible to TRAIL as compared to the metastatic carcino-
ma cells [20]. 
The unchanged secretion of sTRAIL by PMN of
patients with oral cavity cancer in Stage II may be one
of mechanisms responsible for decreased in secretion
of sTRAIL by autologous PBMC observed in the pre-
sent study. It was well established that apart from its
ability to provoke apoptosis: TRAIL was shown to
inhibit T cell activation and proliferation without
inducing T-cell death [7]. Thus, despite of retained
secretion of sTRAIL by PMN, simultaneously
decreased secretion of its by PBMC can be insufficient
for activity of this protein in patients with oral cavity
cancer.  
It is interesting to note that the secretion of sTRAIL
by both kind of cells in patients in Stage IV was
impaired, suggesting a significant defect not only
PBMC but also PMN. It is possible that observed
changes are associated with direct or indirect activity
of the tumor cells. Results obtained after surgery treat-
ment suggest a different effect of tumor cells on the
activity of PMN and PBMC. The defect PMN of can-
cer patients associated with sTRAIL secretion appears
to be more lasting than that observed in PBMC.   
Changed secretion of sTRAIL by both kind of
leukocytes may play a different role in modulating
leukocyte/endothelial cell adhesion. Recently, Sec-
chiero et al. demonstrated that TRAIL has a potential
anti-adhesive effect and that this activity is mediated
by the selective down-regulation of chemokines CCL8
and CXCL10 [21].
The insufficient secretion of sTRAIL by examined
leukocytes, observed in the present study particularly
in patients with advanced disease, may promote the
neoangiogenesis. Cantarella et al. demonstrated that
TRAIL inhibits angiogenesis stimulated by VEGF
[22]. Our previous study on this patient group indicat-
ed a high production of VEGF by PMN and markedly
elevated serum levels of its [23].  
In contrast to changes in sTRAIL secretion by
PMN and PBMC of oral cavity cancer patients, the
secretion of sDR5 by these cells was unchanged. The
lack of changes in the secretion of this inhibitory pro-
tein for TRAIL may be a protective mechanism against
insufficient secretion of its by leukocytes. Our previ-
ous study in this patients showed a diverse relation
between the TNF-α, a prototype member of TNF fam-
ily and its soluble receptor sTNF-Rp75 which play a
regulatory role in TNF-α-mediated reactions [24]. In
the culture supernatants of PMN high TNF-α concen-
trations were accompanying the increased concentra-
tions of sTNFRp75. The excess of TNF-α may balance
the deficit of TRAIL secretion by PMN of examined
patient group. However, the presence of its inhibitory
protein may reduce the TNF activity. Broader prospec-
tive studies are required to explain of this problem.
However, our observations suggest that the estimation
of cytokine secretion should be associated with simul-
taneous estimation of their soluble regulatory proteins. 
It is necessary to note that the changes in the secre-
tion of sTRAIL by PMN and PBMC of patients with
oral cavity cancer were not associated with changes in
its serum levels. The lack of such dependence suggest
that other cells, such as cancer cells, may account for
sTRAIL concentrations in the blood. Studies of Teng
et al. demonstrated that HNSCC cells, involving oral
cavity cancer cells, have ability to secrete TRAIL li-
gand that activates TRAIL receptors [16]. The
decreased serum levels of sTRAIL in patients after
surgery treatment observed in these examinations
appear to confirm role of cancer cells in the secretion
of this protein. 
In conclusion, changed activity of PMN and of
PBMC associated with secretion of sTRAIL may have
different implications for the immune response of
patients with oral cavity cancer cells at different stages
of disease. The lack of changes in sTRAIL secretion
by PMN in patients at early phase of disease may have
a favorable effect on the anti-tumor response. The low
secretion of sTRAIL by both kind of cells in patients
with advanced disease suggests introducing an
immunotherapy modulating these cells for enhanced
secretion of TRAIL or a therapy with exogenous
TRAIL.
Furthermore, since TRAIL/TRAIL-R system may
contribute to the fate of tissue-infiltrating neutrophils
and mononuclear cells, the lack of changes in expres-
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sion of death receptor DR5 make them sensitive to
TRAIL-mediated apoptosis-induced by cancer cells
that is responsible for the impaired activity of these
leukocytes in oral cavity cancer patients. 
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